Atogepant in Real Life in Italy (GIANT)
NCT06136442 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2024-04-10
Summary
Atogepant is an oral, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for the preventive treatment of episodic and chronic migraine (\>= 4 monthly migraine days) with or without medication overuse.
Conditions
- Migraine, Prophylaxis
Interventions
- DRUG
-
Atogepant
atogepant in real life in Italy
Sponsors & Collaborators
-
IRCCS San Raffaele Roma
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-04-09
- Primary Completion
- 2024-06-30
- Completion
- 2024-12-31
- FDA Drug
- Yes
More Related Trials
-
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
NCT03700320 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
NCT03939312 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
NCT04437433 ·Status: COMPLETED ·Phase: PHASE3
-
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136 ·Status: COMPLETED ·Phase: PHASE3
-
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
NCT04740827 ·Status: COMPLETED ·Phase: PHASE3
-
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
NCT06409832 ·Status: RECRUITING
-
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
NCT02848326 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
NCT05861427 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505 ·Status: RECRUITING ·Phase: PHASE3
-
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
NCT03777059 ·Status: COMPLETED ·Phase: PHASE3
-
Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
NCT06882122 ·Status: RECRUITING
-
Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP)
NCT06267664 ·Status: RECRUITING
-
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05707949 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.
NCT06467370 ·Status: COMPLETED
-
Calcitonin Gene-related Peptide Levels in Chronic Migraine
NCT01071096 ·Status: COMPLETED ·Phase: PHASE4
-
Gepant treAtments: EffectIveNess and tolERability (GAINER)
NCT05903027 ·Status: RECRUITING
-
i-NEED: NEw migrainE Drugs Database
NCT07103694 ·Status: RECRUITING
-
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
NCT05264129 ·Status: COMPLETED ·Phase: PHASE4
-
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
NCT06603558 ·Status: RECRUITING
-
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
NCT01617941 ·Status: WITHDRAWN ·Phase: PHASE2
-
Consistency of Response With Rimegepant in Acute Treatment of Migraine
NCT06898047 ·Status: ACTIVE_NOT_RECRUITING
-
CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment
NCT03481400 ·Status: UNKNOWN ·Phase: NA